Impact of optimum diabetes care on the safety of fasting in Ramadan in adult patients with type 2 diabetes mellitus on insulin therapy

被引:16
|
作者
Bashier, Alaaeldin M. K. [1 ]
Bin Hussain, Azza Khalifa [1 ]
Alawadi, Fatheya [1 ]
Alsayyah, Fatima [1 ]
Alsaeed, Maryam [1 ]
Rashid, Fauzia [1 ]
Abdelgadir, Elamin [1 ]
Bachet, Fawzi [1 ]
Abuelkheir, Sona [1 ]
Elsayed, Mohamed [1 ]
Hassanein, Mohamed [1 ]
机构
[1] Dubai Hosp, Endocrine Dept, Dubai, U Arab Emirates
关键词
Ramadan; Flash glucose monitoring; Type; 2; diabetes; Hypoglycemia; Hyperglycemia; HbA1c; Basal insulin; Intensive insulin therapy; OPEN-LABEL; GLARGINE; REPAGLINIDE; MULTICENTER; GLIMEPIRIDE; EFFICACY; REGIMEN;
D O I
10.1016/j.diabres.2019.01.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: We aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetes patients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed. Methods: We included insulin treated patients with type 2 diabetes and we excluded those with co-morbidities. Patients were provided with Ramadan-focused education, FGM before and during Ramadan and medical advice for treatment adjustment. We measured biologic and biometric data before and after Ramadan. Results: HbA1c reduced from 7.9 +/- 1.20 pre-Ramadan to 7.7 +/- 1.5% post Ramadan (p = 0.023). Average peak glucose reading was 330.1 +/- 79.8 mg/dl before Ramadan improved significantly to reach 289.3 +/- 77.7 mg/dl (p = 0.013). Average number of hypoglycemic episodes was higher in intensive insulin group between 1200 and 1800 h (p = 0.028). Conclusion: People with type 2 diabetes treated with insulin who fast Ramadan and who are provided with Ramadan focused patient education, individualized treatment adjustment and FGMS were not at increased safety risks as measured by biochemical, biometric and FGM data. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 50 条
  • [41] Update on Basal Insulin Therapy for Type 2 Diabetes Mellitus
    Patel, Hansita B.
    Witte, Amy P.
    US PHARMACIST, 2021, 46 (11) : 44 - 50
  • [42] Insulin degludec - The impact of a new basal insulin on care in type 2 diabetes
    Khunti, Kamlesh
    Cos, Xavier
    Rutten, Guy
    PRIMARY CARE DIABETES, 2014, 8 (02) : 119 - 125
  • [43] An update on the current characteristics and status of care for Muslims with type 2 diabetes fasting during Ramadan: the DAR global survey 2022
    Hassanein, Mohamed
    Zainudin, Sueziani Binte
    Shaikh, Shehla
    Shaltout, Inass
    Malek, Rachid
    Buyukbese, Mehmet Akif
    Alfadhli, Eman M.
    Shaikh, Khalid
    Hussein, Zanariah
    Eliana, Fatimah
    Hafidh, Khadija
    El Toony, Lobna F.
    Fariduddin, Mohammed
    Alabbood, Majid
    Batais, Mohammed Ali
    Akter, Nazma
    Rosandi, Rulli
    Odhaib, Samih Abed
    Al Amoudi, Reem
    Ahmedani, Muhammad Yakoob
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (09) : 1515 - 1523
  • [44] Insulin therapy during Ramadan fast for Type 1 diabetes patients
    Kassem, HS
    Zantout, MS
    Azar, ST
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2005, 28 (09) : 802 - 805
  • [45] Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan
    Hassanein, Mohamed
    Echtay, Akram Salim
    Malek, Rachid
    Omar, Mahomed
    Shaikh, Shehla Sajid
    Ekelund, Magnus
    Kaplan, Kadriye
    Kamaruddin, Nor Azmi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 135 : 218 - 226
  • [46] Combined metformin and insulin therapy for patients with type 2 diabetes mellitus
    Ponssen, HH
    Elte, JWF
    Lehert, P
    Schouten, JP
    Bets, D
    CLINICAL THERAPEUTICS, 2000, 22 (06) : 709 - 718
  • [47] Insulin Degludec: Reduction of Hypoglycemia during Basal-Bolus Therapy in Patients with Diabetes Mellitus Type 1 or 2
    Luedemann, J.
    Merker, L.
    Milek, K.
    Kaiser, M.
    Wilhelm, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2013, 8 (01) : 35 - 42
  • [48] The role of optimum diabetes care in form of Ramadan focused diabetes education, flash glucose monitoring system and pre-Ramadan dose adjustments in the safety of Ramadan fasting in high risk patients with diabetes
    Hassanein, Mohamed
    Abdelgadir, Elamin
    Bashier, Alaaeldin
    Rashid, Fauzia
    Al Saeed, Maryam
    Khalifa, Azza
    Eltayb, Fawzi
    Abuelkheir, Sona
    Abdellatif, Mohammed
    Sayyah, Fatima
    Khalifa, Suad
    Alawadi, Fatheya
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 150 : 288 - 295
  • [49] Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study)
    Pathan, Md Faruque
    Akter, Nazma
    Mustari, Marufa
    Saifuddin, M.
    Sharifuzzaman, Mirza
    Rahman, Mohammad Motiur
    Ripon, Mohammed
    Mohiuddin, S. M.
    Kamrul-Hasan, A. B. M.
    Hannan, Mohammad Abdul
    Alam, Muhammad Shah
    Mahjabeen, Samira
    Afsana, Faria
    Bakar, Muhammed Abu
    Haq, Tahniyah
    Ahammed, Afsar
    Talukder, Samir Kumar
    Sarkar, Sourav
    Selim, Shahjada
    FRONTIERS IN ENDOCRINOLOGY, 2025, 16
  • [50] Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus
    Kawamori, R.
    Iwamoto, Y.
    Kadowaki, T.
    Iwasaki, M.
    Kim, S. -W.
    Woo, J. -T.
    Baik, S. -H.
    Yoon, K. -H.
    DIABETES OBESITY & METABOLISM, 2009, 11 (09) : 900 - 909